Financial Position - The company reported a strong cash position of $341.5 million, expected to fund operations through 2027 [1][3]. Clinical Trials and Developments - Upstream Bio plans to initiate Phase 3 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in Q1 2027, focusing on a high-dose quarterly regimen of verekitug up to 400 mg [2]. - The Phase 2 VALIANT trial for verekitug showed a 56% reduction in the annualized asthma exacerbation rate (AAER) for the 100 mg every 12 weeks dosing compared to placebo [4]. - Verekitug demonstrated clinically meaningful improvements in lung function, with over 90% of eligible patients transitioning to the long-term extension study [5]. - The Phase 2 VIBRANT trial for CRSwNP showed statistically significant reductions in endoscopic nasal polyp score (NPS) and nasal congestion score (NCS) over a 24-week treatment period [6][7]. Market Reaction - Upstream Bio shares increased by 6.23% to $10.06 at the time of publication [7].
Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data